Showing results (681-690 of 1,524) with videos related to
Sort By:
Pageof 153
CPT: Pharmacometrics & Systems Pharmacology|May 13, 2024
Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetesDouglas E James, Tong Shen, Jeanne S Geiser, et al.CPT: Pharmacometrics & Systems Pharmacology|June 20, 2024
Hepatic OATP1B zonal distribution: Implications for rifampicin-mediated drug-drug interactions explored within a PBPK frameworkMattie Hartauer, William A Murphy, Kim L R Brouwer, et al.CPT: Pharmacometrics & Systems Pharmacology|May 25, 2024
Comparison of dose selection based on target engagement versus inhibition of receptor-ligand interaction for checkpoint inhibitorsSarah A Head, Carter Johnson, Saheli Sarkar, et al.CPT: Pharmacometrics & Systems Pharmacology|May 2, 2024
A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactionsChristina Kovar, Helena Leonie Hanae Loer, Simeon Rüdesheim, et al.CPT: Pharmacometrics & Systems Pharmacology|May 8, 2024
Two new user-friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scalesMartijn van Noort, Martijn RuppertCPT: Pharmacometrics & Systems Pharmacology|May 1, 2024
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancyFarzaneh Salem, Dung Nguyen, Mark Bush, et al.CPT: Pharmacometrics & Systems Pharmacology|November 11, 2023
A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trialsVictoria Kulesh, Igor Vasyutin, Alina Volkova, et al.CPT: Pharmacometrics & Systems Pharmacology|November 10, 2023
Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIVGrace Montepiedra, Elin M Svensson, Weng Kee Wong, et al.CPT: Pharmacometrics & Systems Pharmacology|September 30, 2023
Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept studyYun Seob Jung, Byung Hak Jin, Min Soo Park, et al.CPT: Pharmacometrics & Systems Pharmacology|September 26, 2023
A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohortsJane Knöchel, Linnéa Bergenholm, Eman Ibrahim, et al.Pageof 153